# ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial

> **NCT00839826** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 641 (actual)

## Conditions studied

- Thromboembolism
- Prevention

## Interventions

- **DRUG:** Rivaroxaban (BAY59-7939)
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT00839826
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2003-11
- **Final completion:** 2003-11
- **Target enrollment:** 641 (ACTUAL)
- **Last updated:** 2014-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00839826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00839826, "ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00839826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*